Galliford Try GFRD When the best that a company can find to say about its annual results is that they show a strong underlying performance, then you know that something went wrong. Otherwise it would be claiming a strong financial performance, and that is something which Galliford can not claim. Profit before tax for the year to 30th June fell by 57% and earnings per share by 55%, even though it had the benefit of robust market conditions. The financial performance for the year was impacted by legacy costs in Construction – so that’s alright then ? Can’t be laid at the door of management, that sort of thing, can it ? The shareholders are kept happy with a 17% rise in fully year dividends. To cover itself for the future it is even reduced to blaming the politicians and a board of directors can not sink much lower than that. It is cautious about the future it says, because of the impact of current political uncertainty. That does not seem to be a worry or even a concern for other house builders and in any event politicians and the uncertainty they create have been with us since the dawn of time.
Dunelm Group DULM went ex growth in the year to 1st July with a fall of 0.5% in like for like revenue and profit before tax down by 28.3%, as it tried to cope with a challenging and subdued Homeware and Furniture Market. EBITDA fell by 7.8% and earnings per share by 28% from 50.3p to 36.1p. The ordinary dividend is to be raised by 3.6%. Things improved with the start of the new financial year and sales growth in the first two months is described as being good. What exactly “good’ means in round figures is for some reason being kept a closely guarded secret.
Adv. Medical Solutions AMS continues to go from strength to strength as profit before tax for the six months to 30th June rose by 27% and the interim dividend is increased by 17%. Group revenues grew by 8% at constant currency rates with US revenue rising by 52% and sales of Liquiband strong in all its markets. the company is optimistic about future organic growth.
Surgical Innovations SUN produced strong growth in both revenue and profits in the half year to the 30th June. Revenue rose by 14.1% and last years first half loss of £0.6m was turned into a profit of £0.3m. both sets of figures being at the upper end of the board’s expectations. The acquisition of Elemental Healthcare on the 1st August is regarded as being transformational for the company.
Alliance Pharma APH is increasing its interim dividend by 10% following strong growth from its international brands and an 8% rise in revenue. The integration of Sinclair Pharma has now been completed and “bolt on” acquisitions are now being pursued.